DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

This study is for adults aged 18 or older with certain types of advanced neuroendocrine cancer. To be considered, your cancer cells must have a specific marker called DLL3. Your cancer must also be considered 'locally advanced' (meaning it has spread nearby) or 'metastatic' (meaning it has spread to other parts of the body).

Doctors will also check your general health and how well you can perform daily activities. You would need to have at least one measurable area of cancer that can be tracked. If you have had brain involvement from your cancer that doesn't cause symptoms, you might still be eligible after your doctors confirm it's stable.

However, you cannot take part if you have previously been in this specific trial, are already in another trial, or have been in one within the last 30 days. Certain types of neuroendocrine cancer, like Merkel cell or medullary thyroid cancer, are not included. You also cannot join if you have received certain treatments targeting DLL3 in the past.

If you decide to take part in this study, you will receive the new medicine, BI 764532, and chemotherapy. Both medicines are given through a drip directly into a vein. The treatment may continue for up to three years, as long as you are benefiting from it and can manage any side effects.

You will need to visit the hospital or clinic regularly for check-ups. During these visits, the doctors and nurses will monitor your health closely, check for any unwanted effects from the treatment, and regularly measure the size of your cancer to see how the treatment is working. They will also collect blood samples and perform other tests to keep track of your progress.